The effects of systemic aromatase inhibitors on meibomian glands and corneal structure.
Journal
Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
05
06
2020
accepted:
18
05
2021
revised:
14
05
2021
pubmed:
13
6
2021
medline:
3
6
2022
entrez:
12
6
2021
Statut:
ppublish
Résumé
To evaluate the ocular surface, meibomian glands and corneal structural changes using in vivo confocal microscopy (IVCM) in patients receiving aromatase inhibitor (AI) therapy due to the breast cancer. This prospective observational study included 13 patients undergoing AI therapy. The patients were evaluated before the treatment, at 3- and 6-month timepoints of AI therapy. To examine the ocular surface and tear film, corneal sensitivity (CS) measurement with Cochet-Bonnet Aesthesiometer, tear film break-up time (TBUT), lissamine green (LG) staining, Schirmer I test with anaesthesia (ST) and the ocular-surface disease index (OSDI) questionnaire were performed consecutively. Corneal cell densities and sub-basal nerve plexus were evaluated with IVCM (ConfoScan 4, Nidek, Japan). Finally, quantitative MG drop-out assessment was made using infrared meibography. Shapiro Wilk, Friedman's and Post-hoc Dunn tests were used for the statistical analysis. TBUT, ST scores, basal epithelium, anterior and posterior keratocytes and endothelial cell densities, long and total sub-basal nerve densities were found to be decreased (p < 0.001, p = 0.023, p < 0.001, p = 0.01, p = 0.002, p = 0.004, p < 0.001, p < 0.001), and meiboscore, CS, OSDI scores and sub-basal nerve tortuosity values were increased (p < 0.001, p = 0.015, p = 0.001, p = 0.004) during the treatment. Endothelial pleomorphism rates were lower at the 3- and 6-month timepoints compared to before the treatment (p = 0.04). This study showed that aromatase inhibitor therapy causes deteriorations in many of the ocular-surface parameters and corneal structural changes in relation with the duration of treatment. These patients should be observed during the therapy in terms of the ocular-surface side effects.
Identifiants
pubmed: 34117393
doi: 10.1038/s41433-021-01612-z
pii: 10.1038/s41433-021-01612-z
pmc: PMC9151770
doi:
Substances chimiques
Aromatase Inhibitors
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1185-1193Informations de copyright
© 2021. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.
Références
Lonning PE. The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Ann Oncol. 2011;22:503–14.
pubmed: 20616198
doi: 10.1093/annonc/mdq337
Tomao F, Spinelli G, Vici P, Pisanelli GC, Cascialli G, Frati L, et al. Current role and safety profile of aromatase inhibitors in early breast cancer. Expert Rev Anticancer Ther. 2011;11:1253–63.
pubmed: 21916579
doi: 10.1586/era.11.96
Chatziralli I, Sergentanis T, Zagouri F, Chrysikos D, Ladas I, Zografos GC, et al. Ocular surface disease in breast cancer patients using aromatase inhibitors. Breast J. 2016;22:561–3.
pubmed: 27296769
doi: 10.1111/tbj.12633
Ogueta SB, Schwartz SD, Yamashita CK, Farber DB. Estrogen receptor in the human eye: influence of gender and age on gene expression. Invest Ophthalmol Vis Sci. 1999;40:1906–11.
pubmed: 10440242
Munaut C, Lambert V, Noel A, Frankenne F, Deprez M, Foidart JM, et al. Presence of oestrogen receptor type beta in human retina. Br J Ophthalmol. 2001;85:877–82.
pubmed: 11423466
pmcid: 1724050
doi: 10.1136/bjo.85.7.877
Elliot SJ, Catanuto P, Espinosa-Heidmann DG, Fernandez P, Hernandez E, Saloupis P, et al. Estrogen receptor beta protects against in vivo injury in RPE cells. Exp Eye Res. 2010;90:10–16.
pubmed: 19799898
doi: 10.1016/j.exer.2009.09.001
Eisner A, Falardeau J, Toomey MD, Vetto JT. Retinal hemorrhages in anastrozole users. Optom Vis Sci. 2008;85:301–8.
pubmed: 18451730
doi: 10.1097/OPX.0b013e31816bea3b
Karagoz B, Ayata A, Bilgi O, Uzun G, Unal M, Kandemir EG, et al. Hemicentral retinal artery occlusion in a breast cancer patient using anastrozole. Onkologie. 2009;32:421–3.
pubmed: 19556821
Eisner A, Thielman EJ, Falardeau J, Vetto JT. Vitreo-retinal traction and anastrozole use. Breast Cancer Res Treat. 2009;117:9–16.
pubmed: 18712596
doi: 10.1007/s10549-008-0156-5
Sathiamoorthi S, Ruddy KJ, Bakri SJ. Association of uveitis and macular edema with anastrozole therapy. JAMA Ophthalmol. 2018;136:837–9.
pubmed: 29800041
doi: 10.1001/jamaophthalmol.2018.1700
Schaumberg DA, Buring JE, Sullivan DA, Dana MR. Hormone replacement therapy and dry eye syndrome. JAMA. 2001;286:2114–9.
pubmed: 11694152
doi: 10.1001/jama.286.17.2114
Affinito P, Di Spiezio Sardo A, Di Carlo C, Sammartino A, Tommaselli GA, Bifulco G, et al. Effects of hormone replacement therapy on ocular function in postmenopause. Menopause. 2003;10:482–7.
pubmed: 14501611
doi: 10.1097/01.GME.0000063568.84134.35
Berman ER. Tears. In: Biochemistry of the Eye. Boston: Springer US; 1991. p. 63–88.
Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab. 2005;90:3847–53.
pubmed: 15827095
doi: 10.1210/jc.2005-0212
Rizner TL, Thalhammer T, Ozvegy-Laczka C. The importance of steroid uptake and intracrine action in endometrial and ovarian cancers. Front Pharmacol. 2017;8:346.
pubmed: 28674494
pmcid: 5474471
doi: 10.3389/fphar.2017.00346
Labrie F, Belanger A, Luu-The V, Labrie C, Simard J, Cusan L, et al. DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids. 1998;63:322–8.
pubmed: 9618795
doi: 10.1016/S0039-128X(98)00007-5
Sullivan DA, Rocha EM, Aragona P, Clayton JA, Ding J, Golebiowski B, et al. TFOS DEWS II Sex, Gender, and Hormones Report. Ocul Surf. 2017;15:284–333.
pubmed: 28736336
doi: 10.1016/j.jtos.2017.04.001
Versura P, Giannaccare G, Campos EC. Sex-steroid imbalance in females and dry eye. Curr Eye Res. 2015;40:162–75.
pubmed: 25290221
doi: 10.3109/02713683.2014.966847
Sullivan DA, Sullivan BD, Ullman MD, Rocha EM, Krenzer KL, Cermak JM, et al. Androgen influence on the meibomian gland. Invest Ophthalmol Vis Sci. 2000;41:3732–42.
pubmed: 11053270
Sullivan DA, Rocha EM, Ullman MD, Kreuzer KL, Gao J, Toda I et al. Androgen Regulation of the Meibomian Gland. In: Sullivan DA, Dartt DA, Meneray MA (eds). Lacrimal Gland, Tear Film, and Dry Eye Syndromes 2: Basic Science and Clinical Relevance. Boston: Springer US; 1998. p. 327–31.
Liu M, Richards SM, Schirra F, Yamagami H, Sullivan BD, Sullivan DA. Identification of androgen-regulated genes in the lacrimal gland. Adv Exp Med Biol. 2002;506:129–35.
pubmed: 12613899
doi: 10.1007/978-1-4615-0717-8_17
Smith RE. The tear film complex: pathogenesis and emerging therapies for dry eyes. Cornea. 2005;24:1–7.
pubmed: 15604860
doi: 10.1097/01.ico.0000141486.56931.9b
Inglis H, Boyle FM, Friedlander ML, Watson SL. Dry eyes and AIs: If you don’t ask you won’t find out. Breast. 2015;24:694–8.
pubmed: 26422124
doi: 10.1016/j.breast.2015.08.008
Turaka K, Nottage JM, Hammersmith KM, Nagra PK, Rapuano CJ. Dry eye syndrome in aromatase inhibitor users. Clin Exp Ophthalmol. 2013;41:239–43.
pubmed: 22957932
Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5:108–52.
Irkec MT, Group TOS. Reliability and validity of Turkish translation of the ocular surface disease index (OSDI) in dry eye syndrome. Invest Ophthalmol Vis Sci. 2007;48:408–408.
Pult H, Riede-Pult B. Comparison of subjective grading and objective assessment in meibography. Cont Lens Anterior Eye. 2013;36:22–27.
pubmed: 23108007
doi: 10.1016/j.clae.2012.10.074
Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010;28:3784–96.
pubmed: 20625130
pmcid: 5569672
doi: 10.1200/JCO.2009.26.3756
Spelsberg H, Klueppel M, Reinhard T, Glaeser M, Niederacher D, Beckmann MW, et al. Detection of oestrogen receptors (ER) alpha and beta in conjunctiva, lacrimal gland, and tarsal plates. Eye (Lond). 2004;18:729–33.
doi: 10.1038/sj.eye.6701314
Song X, Zhao P, Wang G, Zhao X. The effects of estrogen and androgen on tear secretion and matrix metalloproteinase-2 expression in lacrimal glands of ovariectomized rats. Invest Ophthalmol Vis Sci. 2014;55:745–51.
pubmed: 24334444
doi: 10.1167/iovs.12-10457
Krenzer KL, Dana MR, Ullman MD, Cermak JM, Tolls DB, Evans JE, et al. Effect of androgen deficiency on the human meibomian gland and ocular surface. J Clin Endocrinol Metab. 2000;85:4874–82.
pubmed: 11134156
Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014;383:1041–8.
pubmed: 24333009
doi: 10.1016/S0140-6736(13)62292-8
Gibson E, Stapleton F, Dear R, Wolffsohn JS, Golebiowski B. Dry eye signs and symptoms in aromatase inhibitor treatment and the relationship with pain. Ocul Surf. 2020;18:108–13.
pubmed: 31669349
doi: 10.1016/j.jtos.2019.10.008
Suzuki T, Schirra F, Richards SM, Jensen RV, Sullivan DA. Estrogen and progesterone control of gene expression in the mouse meibomian gland. Invest Ophthalmol Vis Sci. 2008;49:1797–808.
pubmed: 18436814
doi: 10.1167/iovs.07-1458
Kam W, Sullivan D. Suppressive effects of 17β-estradiol on immortalized human meibomian gland epithelial cells. Invest Ophthalmol Vis Sci. 2013;54:4316–4316.
Darabad RR, Suzuki T, Richards SM, Jensen RV, Jakobiec FA, Zakka FR, et al. Influence of aromatase absence on the gene expression and histology of the mouse meibomian gland. Invest Ophthalmol Vis Sci. 2013;54:987–98.
pubmed: 23233261
doi: 10.1167/iovs.12-10992
Tong L, Gupta PK. Need for animal models of meibomian gland dysfunction. Ophthalmol Ther. 2016;5:129–34.
pubmed: 27837409
pmcid: 5125130
doi: 10.1007/s40123-016-0070-6
Sacchetti M, Lambiase A. Diagnosis and management of neurotrophic keratitis. Clin Ophthalmol. 2014;8:571–9.
pubmed: 24672223
pmcid: 3964170
Cai D, Zhu M, Petroll WM, Koppaka V, Robertson DM. The impact of type 1 diabetes mellitus on corneal epithelial nerve morphology and the corneal epithelium. Am J Pathol. 2014;184:2662–70.
pubmed: 25102563
pmcid: 4188872
doi: 10.1016/j.ajpath.2014.06.016
Benitez-Del-Castillo JM, Acosta MC, Wassfi MA, Diaz-Valle D, Gegundez JA, Fernandez C, et al. Relation between corneal innervation with confocal microscopy and corneal sensitivity with noncontact esthesiometry in patients with dry eye. Invest Ophthalmol Vis Sci. 2007;48:173–81.
pubmed: 17197530
doi: 10.1167/iovs.06-0127
Labbe A, Alalwani H, Van Went C, Brasnu E, Georgescu D, Baudouin C. The relationship between subbasal nerve morphology and corneal sensation in ocular surface disease. Invest Ophthalmol Vis Sci. 2012;53:4926–31.
pubmed: 22695962
doi: 10.1167/iovs.11-8708
Steger B, Speicher L, Philipp W, Bechrakis NE. In vivo confocal microscopic characterisation of the cornea in chronic graft-versus-host disease related severe dry eye disease. Br J Ophthalmol. 2015;99:160–5.
pubmed: 25138762
doi: 10.1136/bjophthalmol-2014-305072
Zhang X, Chen Q, Chen W, Cui L, Ma H, Lu F. Tear dynamics and corneal confocal microscopy of subjects with mild self-reported office dry eye. Ophthalmology. 2011;118:902–7.
pubmed: 21146227
doi: 10.1016/j.ophtha.2010.08.033
Belmonte C, Nichols JJ, Cox SM, Brock JA, Begley CG, Bereiter DA, et al. TFOS DEWS II pain and sensation report. Ocul Surf. 2017;15:404–37.
pubmed: 28736339
pmcid: 5706540
doi: 10.1016/j.jtos.2017.05.002
Tachibana M, Kasukabe T, Kobayashi Y, Suzuki T, Kinoshita S, Matsushima Y. Expression of estrogen receptor alpha and beta in the mouse cornea. Invest Ophthalmol Vis Sci. 2000;41:668–70.
pubmed: 10711679
Tachibana M, Kobayashi Y, Kasukabe T, Kawajiri K, Matsushima Y. Expression of androgen receptor in mouse eye tissues. Invest Ophthalmol Vis Sci. 2000;41:64–66.
pubmed: 10634602
Suzuki T, Kinoshita Y, Tachibana M, Matsushima Y, Kobayashi Y, Adachi W, et al. Expression of sex steroid hormone receptors in human cornea. Curr Eye Res. 2001;22:28–33.
pubmed: 11402376
doi: 10.1076/ceyr.22.1.28.6980
Hadeyama T, Nakayasu K, Ha NT, Nakamura S. Expression of estrogen receptors alpha and beta, androgen receptors and progesterone receptors in human cornea. Nippon Ganka Gakkai Zasshi. 2002;106:557–64.
pubmed: 12385120
Wickham LA, Gao J, Toda I, Rocha EM, Ono M, Sullivan DA. Identification of androgen, estrogen and progesterone receptor mRNAs in the eye. Acta Ophthalmol Scand. 2000;78:146–53.
pubmed: 10794246
doi: 10.1034/j.1600-0420.2000.078002146.x